title: Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation.
abstract: A polysyloxane vaginal ring containing 1g of natural progesterone was developed as luteal supplementation for women treated with IVF-embryo transfer and for agonadal women participating in an oocyte donation programme. The ring provides continuous release of progesterone (10-20 nmol/l) for 90 days. The efficacy of this form of progesterone supplementation was evaluated in two multicentre prospective randomized trials. IVF-embryo transfer trial: After oocyte aspiration, 505 women were randomly allocated to progesterone supplementation with vaginal ring or i.m. progesterone (50 mg/day). The clinical pregnancy rate was 36.6% in both groups. Implantation rate was 15.9% in the vaginal ring and 16.0% in i.m. progesterone. Oocyte donation trial: After endometrial proliferation with micronized oestradiol, 153 women were allocated to progesterone replacement with a vaginal ring or i.m. progesterone (100 mg/day). Clinical pregnancy rate was 39.8 and 28.6% respectively. Implantation rate was significantly higher with the vaginal ring compared with i.m. progesterone (19.9 and 11.6% respectively, P = 0.006). The vaginal ring is a novel development which provides continuous release of progesterone for 90 days. In IVF-embryo transfer, its effectiveness is similar to daily i.m. injections. In oocyte donation the ring provides a progestative milieu which improves the implantation rate and eliminates the discomfort of daily i.m. injections.
authors.affiliation: Unidad de Medicina Reproductiva, Clínica Las Condes, Santiago, Chile. umrclc@entelchile.net
authors.forename: F
authors.initials: F
authors.lastname: Zegers-Hochschild
authors.forename: J P
authors.initials: JP
authors.lastname: Balmaceda
authors.forename: C
authors.initials: C
authors.lastname: Fabres
authors.forename: V
authors.initials: V
authors.lastname: Alam
authors.forename: A
authors.initials: A
authors.lastname: Mackenna
authors.forename: E
authors.initials: E
authors.lastname: Fernández
authors.forename: I M
authors.initials: IM
authors.lastname: Pacheco
authors.forename: M S
authors.initials: MS
authors.lastname: Sepúlveda
authors.forename: S
authors.initials: S
authors.lastname: Chen
authors.forename: C
authors.initials: C
authors.lastname: Borrero
authors.forename: E
authors.initials: E
authors.lastname: Borges
mesh_terms: D000328:Adult; D016503:Drug Delivery Systems; D010064:Embryo Implantation; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D006801:Humans; D007267:Injections; D018587:Oocyte Donation; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage*; D011446:Prospective Studies; D014621:Vagina
chemical_list: D011374:Progesterone